Skip to main content
Intensive Care Medicine Experimental
Download PDF

Volume 3 Supplement 1

ESICM LIVES 2015

  • Poster presentation
  • Open access
  • Published:

Dopaminergic Challenge With Bromocriptine in Patients With Severe Brain Injury

Intensive Care Medicine Experimental volume 3, Article number: A485 (2015) Cite this article

Introduction

Bromocriptine Mesylate (BC) is an ergot derivative with potent dopamine receptor agonist activity. It is licensed to reduce plasma levels of prolactin. BC has central nervous effects, and is used in patients with Parkinson's disease. There are few randomized controlled trials with BC conducted in moderate brain injury (BI) with conflicting results (1). We aim to present our single center experience on dopaminergic challenge using off-label BC in patients with severe BI.

Methods

Glasgow Coma Score (GCS) are 3-10 (GCS: worst score = 3, best score = 15) at beginning of BC administration. Patients received 2.5mg of BC q6h after hemodynamic stability was ensured and no further neurologic improvement was observed during course of management. BC was started and discontinued on the discretion of the ICU team. Long term cognitive tests are under assessment.

Results

A total of 18 patients were treated with BC. the average age was 48.9 (82-18) (12M/6F).

Conclusions

Our results show some neurologic improvement as assessed by GCS. More research is warranted before BC can be recommended in BI.

Table 1 GCS of patients on admission, beginning treatment, end of treatment and discharge. GCS of patients on admission, beginning treatment.
Full size table

References

  1. Frenette AJ, Kanji S, Rees L, Williamson DR, Perreault MM, Turgeon AF, et al: Efficacy and safety of dopamine agonists in traumatic brain injury: a systematic review of randomized controlled trials. J Neurotrauma. 2012, 29 (1): 1-18. 10.1089/neu.2011.1812.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Selcuk University Medicine Faculty, Anesthesiology and Reanimation, Konya, Turkey

    JB Celik, A Duman, O Arun, IO Onal, O Ilban & AE Sonmez

Authors
  1. JB Celik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Duman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O Arun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. IO Onal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O Ilban
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. AE Sonmez
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Celik, J., Duman, A., Arun, O. et al. Dopaminergic Challenge With Bromocriptine in Patients With Severe Brain Injury. ICMx 3 (Suppl 1), A485 (2015). https://doi.org/10.1186/2197-425X-3-S1-A485

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/2197-425X-3-S1-A485

Keywords